Cancer Archives

More News! 14 Oct 2022

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute positions it […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS) company, are collaborating to improve manufacturing and analytic procedures to develop personalized cell and gene therapies for cancer patients. aCGT Vector will provide its point-of-care, GMP-licensed manufacturing platform to validate Xcellbio’s […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Odyssey Therapeutics raises $168M for oncology medicine portfolio

Biotech company Odyssey Therapeutics, Inc. has announced it has raised $168 million in series B financing. Odyssey Therapeutics is working on next generation precision immunomodulators and oncology medicines. The current round brings the total capital raised to $386 million. The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

T-cell therapy platform trial begins in adults with blood cancers

SMART102, a human T-lymphoid progenitor cell injection derived from cord blood using Smart Immune’s ProTcell platform, has entered clinical testing. The trial is being sponsored and led by Great Paris University Hospitals (AP-HP). Smart Immune SAS is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Adalta and GPCR Therapeutics to collaborate on novel cancer treatments

AdAlta Limited and GPCR Therapeutics Inc, are set to collaborate to evaluate AdAlta’s CXCR4 inhibiting i‑bodies as cancer therapeutics, using GPCR Therapeutics’ combination inhibition approach. AdAlta said its i-body platform is suited to engaging an important class of drug targets called G-protein coupled receptors (GPCRs). One of these GPCRs is known as CXCR4. In addition […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Oct 2022

Boston Cell Standards wins FDA $510K clearance for anatomic pathology controls

A company standardizing cancer diagnostic tissue testing with the first immunohistochemistry (IHC) laboratory reference standards has received $510,000 clearance from the U.S. Food and Drug Administration (FDA). The money will go towards Boston Cell Standards IHControls panel for evaluating breast cancers. The clearance represents regulatory approval. “IHControls represent a giant step forward in standardization in […]

October 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 11 Oct 2022

TILT Biotherapeutics doses first U.S. patient in ovarian cancer immunotherapy trial

TILT Biotherapeutics says the first U.S. patient has been dosed in its ovarian cancer trial using its oncolytic adenovirus, TILT-123. The company said TILT-123 has the potential to be first-in-class for this indication. The open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with MSD’s (a tradename of Merck & Co., […]

October 11, 2022 - 2 minutesmins - By Jim Cornall

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 10 Oct 2022

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug

China’s National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for JW Therapeutics’ anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection. Also known as relma-cel, the product has the trade name Carteyva. It is used for the treatment of adult patients with follicular lymphoma that is […]

October 10, 2022 - 3 minutesmins - By Jim Cornall

More News! 10 Oct 2022

RadioMedix announces a $40 million series A financing for targeted alpha therapy platform

A company committed to advancing treatments for rare and aggressive cancers has received a series A funding of $40 million. Clinical stage biotech, RadioMedix, Inc. announced the agreement with an entity related to Portland Investment Counsel Inc. (Portland), on Friday (October 7). RadioMedix is committed to the advancement of a targeted alpha therapy (TAT) pipeline […]

October 10, 2022 - 3 minutesmins - By Liza Laws

News and Trends 10 Oct 2022

Biocartis starts European commercialization of liver cancer test

Biocartis Group NV has started the commercialization in Europe of the HepatoPredict test as a CE-IVD marked manual kit. The test, developed by Portuguese biotech company Ophiomics, is a prognostic diagnostic test that supports the decision of liver transplantation in patients with hepatocellular carcinoma (HCC). Herman Verrelst, chief executive officer of Biocartis, said: “We are […]

October 10, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies

Odyssey Therapeutics raises $168M for oncology medicine portfolio

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

T-cell therapy platform trial begins in adults with blood cancers

Adalta and GPCR Therapeutics to collaborate on novel cancer treatments

Boston Cell Standards wins FDA $510K clearance for anatomic pathology controls

TILT Biotherapeutics doses first U.S. patient in ovarian cancer immunotherapy trial

The biggest private biotech investments in September 2022

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug

RadioMedix announces a $40 million series A financing for targeted alpha therapy platform

Biocartis starts European commercialization of liver cancer test

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!